Most recent by Robert Stott
ELATIVE: Iqirvo ‘effective, well-tolerated treatment option’ for advanced-stage PBC
PHILADELPHIA — Iqirvo demonstrated significant biochemical response and alkaline phosphatase normalization in patients with both early- and advanced-stage primary biliary cholangitis, according to late-breaking data presented here.
‘No meaningful difference’: Zymfentra monotherapy as effective as combined therapy for IBD
PHILADELPHIA — Zymfentra as monotherapy was no more effective when combined with immunosuppressants for maintenance therapy in patients with Crohn’s disease or ulcerative colitis, according to post-hoc analysis presented here.
Cendakimab sustains ‘promising results’ for safety, efficacy in EoE at 48 weeks
PHILADELPHIA — A once-weekly 360 mg dose of cendakimab sustained improvements in symptoms and endoscopic/histologic features of eosinophilic esophagitis at 48 weeks, according to data presented at the ACG Annual Scientific Meeting.
Top 25 US insurers fail to provide coverage for intragastric balloon, endoscopic sleeve
PHILADELPHIA — None of the top 25 insurers in the United States offer explicit policy coverage for primary or revisional endoscopic bariatric therapies, according to data presented at the ACG Annual Scientific Meeting.
Drug rivals face off in PBC after FDA hands down 2 new approvals, 1 advisory snub
The long-stagnant primary biliary cholangitis drug market has seen renewed attention in the past 3 months with the addition of two FDA-approved therapy options as well as a costly ruling from an FDA advisory committee.
AI model highly accurate in differentiating pancreatic cystic, solid lesions on ultrasound
PHILADELPHIA — An AI model achieved high accuracy in detecting and distinguishing between cystic and solid pancreatic focal lesions during endoscopic ultrasound procedures, according to data presented at the ACG Annual Scientific Meeting.
Drug rivals face off in PBC after FDA hands down 2 new approvals, 1 advisory snub
The long-stagnant primary biliary cholangitis drug market has seen renewed attention in the past 3 months with the addition of two FDA-approved therapy options as well as a costly ruling from an FDA advisory committee.
After July surge, FDA approvals for GI settle into summer lull: What you may have missed
Following a July boom in game-changing FDA approvals for gastroenterology, including the first blood test for colorectal cancer, the agency has succumbed to the summer lull with only three approvals for GI to close out the season.
VIDEO: Specialties, guidelines still dueling over ‘dilemma of GLP-1 agonists’ in endoscopy
In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that the booming popularity in glucagon-like peptide-1 agonists have spurred an interspecialty “dilemma” regarding aspiration risks in the endoscopy suite.
VIDEO: Without universal screening, ‘tiny’ hepatitis D could ‘wreak havoc’ globally
In a Healio video exclusive, Edward V. Loftus Jr., MD, warned that, despite being the smallest virus capable of causing human disease, hepatitis delta virus holds an outsized global impact as the most severe form of viral hepatitis.